Use of oral methadone as an analgesic: Review of the cardiotoxic side effects

Clinical Medicine Insights: Therapeutics

Volumn 2, Issue , 2010, Pages 299-305

  Kumar, Pramod ^a  

^a Indian Register of Shipping   (India)

Author keywords

Analgesics; Cardiotoxicity; Methadone; Opioid; QTc interval

Indexed keywords

METHADONE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; PHENOTHIAZINE; PROPRANOLOL; TRICYCLIC ANTIDEPRESSANT AGENT; VERAPAMIL;

ANALGESIC ACTIVITY; ARTICLE; BRADYCARDIA; CANCER PAIN; CARDIOTOXICITY; CLINICAL PROTOCOL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG USE; HEART MUSCLE CONTRACTILITY; HEROIN DEPENDENCE; HUMAN; NEUROPATHIC PAIN; OPIATE ADDICTION; PAIN; PRESCRIPTION; QT PROLONGATION; RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; SHORT QT SYNDROME; SIDE EFFECT;

EID: 77952703057     PISSN: None     EISSN: 1179559X     Source Type: Journal    
DOI: 10.4137/cmt.s3579     Document Type: Article

References (39)

1. Goldstein A, Herrera J. Heroin addict and methadone treatment in Albuquerque: a 22 year follow up. Drug alcohol Depend. 1995;40:130-50.
2. Health Canada. Best Practices. Methadone Maintenance Treatment. Ottawa: Minister of Public Works and Government Services, 2002. Available from URL; http://www.hc-sc.gc.ca/hecs-sesc/cds/pdf/methadone_treatment_best_practices.pdf.
3. Fishman SM, Wilsey B, Mahajan G, Molina P. Methadone reincarnated: novel clinical applications with related concerns. Pain Med. 2002;3:339-348.
4. Fredheim OM, Moksnes K, Borchgrevink PC, Kaasa S, Dale O. Clini-cal pharmacology of methadone for pain. Acta Anaesthesiologica Scand. 2008;52:879-89.
5. Corkery JM, Schifano F, Ghodse AH, Oyefeso A. The effects of methadone and its role in fatalities. Hum Psychopharmacol Cli Exp. 2004;19:565-76.
6. Ballesteros MF, Dudnitz DS, Sanford CP, Gilchrist J, Agyekum GA, Butts J. Increase in death due to methadone in North Carolina. JAMA. 2003;290:40-5.
7. Auricombe M, Franques P, Tignol J. Deaths attributable to methadone vs. buprenorphine in France. JAMA. 2001;285:45.
8. Deamer RL, Wilson DR, Clark DS, Prichard JG. Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM). J Addict Dis. 2001;20:7-14.
9. Jaffe JH. Can LAAM, like Lazarus, come back from the dead? Addiction. 2007;102:1342-43.
10. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Cli Pharmacokinet. 2002;41:1153-93.
11. Buster MC, Van Brussel GH, Van de Brink W. An increase in overdose mortality during first two week after entering or re-entering methadone treatment in Amsterdam. Addiction. 2002;97:993-1001.
12. Dean M. Opioid in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28:497-504.
13. Ebert B, Thorkildsen C, Andersen S, Christrup LL, Hjeds H. Opioid analgesics as noncompetitive N-methyl-Daspartate (NMDA) antagonists. Biochem Pharmacol. 1998;56:553-9.
14. Sawe J, Hansen J, Giniman C, Harevig P, Jakobsson PA, Nilsson MI. Patient controlled dose regimenof methadone for chronic cancer pain. Br Med J. 1981;282:771-3.
15. Bruera E, Sweeney C. Methadone use in cancer patients with pain: a review. J Palliative Med. 2002;5:127-38.
16. Morley JS, Bridson J, Nash TP, Miles JB, White S, Makin MK. Low dose methadone has an analgesic effects in neuropathic pain: a double blind randomized controlled crossover trial. J Palliative Med. 2003;17:576-87.
17. Quigley C. Opioid switching to improve pain relief and drug tolerability. The Cochrane database of systematic reviews. 2004; CD004847.
18. Quigely C. Opioid switching to improve pain relief and drug tolerability. The Cochrane Database of Systematic Reviews. 2004: CD004847.
19. Toombs JD, Kral LA. Methadone treatment for pain states. Am Fam Physician. 2005;71:1353-58.
20. Mercadante S, Casuccio A, Calderone L. Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol. 1999;17:3307-12.
21. Ripamonti C, Groff L, Brunelli C, Polastri D, Starrakis A, De Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 1998;16:3216-21.
22. Methadone use for pain control may result in death and life threatening changes in breathing and heart beat. November 27, 2006. Food drug and Administration. Available at: www.fda.gov/cder/drug/advisory/methadone.htm Accessed on October 29, 2009.
23. David R, Guay P. Cardiotoxicity of oral methadone as an analgesicrecommendation for safe Use. Cli Med Therap. 2009;1:1073-1101.
24. Eikenburg DC, Stickney JL. Anti-cholinesterase activity of 1-alphaacetyl- methadol: relationship to bradycardia. Gen Pharmacol. 1979;10:195-200.
25. Rendig SV, Amsterdam EA, Henderson GL, et al. Comparative cardiac contractile actions of six narcotic analgesics: morphine, meperidine, pentazocine, fentanyl, methadone, and l-α-acetylmethadol (LAAM). J Pharmacol Exp Ther. 1980;215:259-65.
26. Kang J, Chen XL, Wong H, et al. Interactions of the narcotic l-α-acetylmethadol with human cardiac K+ channels. Eur J Pharmacol. 2003;458:25-9.
27. Eap CB, Crettol S, Rougier JS, et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther. 2007;81:719-28.
28. Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther. 2006;316:1098-1106.
29. Athanasos P, Farquharson AL, Compton P, Psaltis P, Hay J. Electrocardiogram characteristics of methadone and buprenorphine maintained subjects. J Addictive Dis. 2008;27:31-5.
30. Katchman AN, McGroary KA, Kilborn MJ, et al. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K+ currents. J Pharmacol Exp Ther. 2002;303:688-94.
31. Brugada R, Hong K, Dumaine R, et al. Sudden death associated with short QT syndrome linked to mutations in HERG. Circulation. 2004;109:30-5.
32. Bellocq C, van Ginneken AC, Bezzina CR, et al. Mutation in KCNQ1 gene leading to the short QT-interval syndrome Circulation. 2004;109: 2394-7.
33. Priori SG, Pandit SV, Rivolta I, et al. A novel form of short QT syndrome in caused by a mutation in the KCNJ2 gene. Circ Res. 2005;96:800-7.
34. Gussak I, Brugada P, Brugada J, et al. Idiopathic short QT interval: a new clinical syndrome? Cardriology. 2000;94:99-102.
35. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: a familial cause of sudden death. Circulation. 2004;109:30-5.
36. Wolpert C, Schimpf R, Giustetto C, et al. Further insights into the effect of quinidine in short QT syndrome caused by mutation in HERG. J Cardiovasc Electrophysiol. 2005;16:54-8.
37. Junttila MJ, Gonzalez M, Lizotte E. Induced Brugada-type electrocardiogram, a sign for imminent malignant arrhythmias. Circulation. 2008;117:1890-3.
38. Krantz MJ, Martin J, Stimmel B. QTc interval screening in methadone treatment. Ann Intern Med. 2009;150 (published online on 1/20/09 at www.annals.org).
39. Bruera E, Fainsinger R, Moore M, Thibault R, Spoldi E, Ventafridda V. Local toxicity with subcutaneous methadone. Experience of two centers. Pain. 1991;45:141-3.